Mediar Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
238 Main St, Cambridge, Massachusetts, 0...Phone Number
(617) 954-9356Website
www.mediartx.comRevenue
$12.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Mediar Therapeutics
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar's goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach.Explore more
Mediar Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mediar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Mediar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Mediar Therapeutics is spiking on competitors!
Check if Mediar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Mediar Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Mediar Therapeutics launches new products
Funding: Get notified immidiatlly once Mediar Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Mediar Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Mediar Therapeutics
Recommended Actions
Reach out to Masked Content who joined Mediar Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Mediar Therapeutics
Compare insights from companies similar to Mediar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mediar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mediar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mediar Therapeutics.
Mediar Therapeutics financials insights
Gather financial insights about Mediar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$85M
Other Financing Round
$20M
2026
Series B
$76M
Mediar Therapeutics Tech Stack
A closer look at the technologies used by Mediar Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Mediar Therapeutics News & Media
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
Series B Co-led by New Investors Amplitude Ventures and ICG MTX-474 Global Phase 2a study Initiated in Systemic Sclerosis (SSc) MTX-463 Global Phase 2a Study in Idiopathic Pulmonary Fibrosis (IPF) Enrolling & Partnered with Lilly MTX-439 Advancing to Phase 1 studies for Fibrosis...Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
First-in-class agent targets WISP1 in patients with IPF Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC) at 24 Weeks BOSTON, June 5, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed...Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Mediar to advance MTX-463 through an IPF Phase 2 trial, with expected initiation in 1H 2025 BOSTON, Jan. 10, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression,...Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis
First cohort of participants dosed in Phase 1 trial evaluating safety and tolerability of MTX-474, a human IgG1 antibody designed to neutralize EphrinB2 signaling Phase 1 study for MTX-463, an antibody neutralizing WISP1-mediated fibrotic signaling, enrolling ahead of schedule with most...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mediar Therapeutics
Sign Up For FreeTo access detailed company insights
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progres... Read More
